Seppo W Langer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9723241/publications.pdf

Version: 2024-02-01

100 papers	3,474 citations	172457 29 h-index	155660 55 g-index
102 all docs	102 docs citations	102 times ranked	3745 citing authors

#	Article	IF	Citations
1	Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Annals of Oncology, 2013, 24, 152-160.	1.2	792
2	Head-to-Head Comparison of ⁶⁴Cu-DOTATATE and ⁶⁸Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors. Journal of Nuclear Medicine, 2017, 58, 451-457.	5.0	163
3	A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Annals of Oncology, 2007, 18, 338-345.	1.2	149
4	Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Annals of Oncology, 2007, 18, 546-550.	1.2	136
5	⁶⁴Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with ¹¹¹In-DTPA-Octreotide in 112 Patients. Journal of Nuclear Medicine, 2015, 56, 847-854.	5.0	115
6	Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta OncolÃ³gica, 2014, 53, 1284-1297.	1.8	99
7	Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics, 2015, 5, 119-176.	2.6	87
8	The Impact of a Multidimensional Exercise Intervention on Physical and Functional Capacity, Anxiety, and Depression in Patients With Advanced-Stage Lung Cancer Undergoing Chemotherapy. Integrative Cancer Therapies, 2015, 14, 341-349.	2.0	82
9	High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncology, The, 2021, 22, 321-331.	10.7	74
10	Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. Annals of Surgical Oncology, 2016, 23, 1721-1728.	1.5	73
11	Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Management and Research, 2014, 6, 357.	1.9	72
12	⁶⁴Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with ⁶⁸Ga-DOTATOC in 60 Patients. Journal of Nuclear Medicine, 2015, 56, 1895-1900.	5.0	67
13	Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas. Scientific World Journal, The, 2012, 2012, 1-4.	2.1	57
14	PET/CT imaging in response evaluation of patients with small cell lung cancer. Lung Cancer, 2006, 54, 41-49.	2.0	54
15	A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. Neuroendocrinology, 2021, 111, 883-894.	2.5	54
16	Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemotherapy and Pharmacology, 2006, 57, 125-128.	2.3	53
17	¹⁸F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study. Journal of Nuclear Medicine, 2021, 62, 808-815.	5.0	53
18	Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Annals of Oncology, 2001, 12, 405-410.	1.2	52

#	Article	IF	Citations
19	Maleimide Is a Potent Inhibitor of Topoisomerase II in Vitro and in Vivo: A New Mode of Catalytic Inhibition. Molecular Pharmacology, 2002, 61, 1235-1243.	2.3	46
20	Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. European Journal of Surgical Oncology, 2017, 43, 1682-1689.	1.0	46
21	Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial. Lung Cancer, 2020, 145, 76-82.	2.0	43
22	Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas. Journal of Cancer, 2014, 5, 628-632.	2.5	39
23	Early initiated postoperative rehabilitation reduces fatigue in patients with operable lung cancer: A randomized trial. Lung Cancer, 2018, 126, 125-132.	2.0	39
24	DEXRAZOXANE - A PROMISING ANTIDOTE IN THE TREATMENT OF ACCIDENTAL EXTRAVASATION OF ANTHRACYCLINES. Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery, 2003, 37, 174-175.	0.6	37
25	Perioperative Rehabilitation in Operable Lung Cancer Patients (PROLUCA). Integrative Cancer Therapies, 2016, 15, 455-466.	2.0	34
26	P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms. BMC Cancer, 2020, 20, 27.	2.6	34
27	Extravasation of Chemotherapy. Current Oncology Reports, 2010, 12, 242-246.	4.0	32
28	Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta OncolÃ³gica, 2021, 60, 931-941.	1.8	32
29	Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer Chemotherapy and Pharmacology, 2003, 52, 167-174.	2.3	31
30	Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients. Journal of Nuclear Medicine, 2016, 57, 1851-1857.	5.0	29
31	⁶⁴Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After Injection. Journal of Nuclear Medicine, 2021, 62, 73-80.	5.0	29
32	Surgical Management, Preoperative Tumor Localization, and Histopathology of 80 Patients Operated on for Insulinoma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6129-6138.	3.6	28
33	Anthracycline Extravasation: A Comprehensive Review of Experimental and Clinical Treatments. Tumori, 2009, 95, 273-282.	1.1	27
34	⁶⁴Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms. Journal of Nuclear Medicine, 2020, 61, 1491-1497.	5.0	27
35	â€œEXHALEâ€• exercise as a strategy for rehabilitation in advanced stage lung cancer patients: a randomized clinical trial comparing the effects of 12Âweeks supervised exercise intervention versus usual care for advanced stage lung cancer patients. BMC Cancer, 2013, 13, 477.	2.6	26
36	Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 83 Patients. PLoS ONE, 2015, 10, e0117627.	2.5	26

#	Article	IF	Citations
37	Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. British Journal of Cancer, 1999, 80, 412-418.	6.4	25
38	Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. PLoS ONE, 2017, 12, e0187667.	2.5	24
39	Surgery of the primary tumour in 201 patients with highâ€grade gastroenteropancreatic neuroendocrine and mixed neuroendocrineâ€nonâ€neuroendocrine neoplasms. Journal of Neuroendocrinology, 2021, 33, e12967.	2.6	23
40	A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer. Lung Cancer, 2012, 78, 63-69.	2.0	22
41	Perioperative rehabilitation in operation for lung cancer (PROLUCA) â€“ rationale and design. BMC Cancer, 2014, 14, 404.	2.6	22
42	Semiautomatic Tumor Delineation for Evaluation of ⁶⁴Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume. Journal of Nuclear Medicine, 2021, 62, 1564-1570.	5.0	20
43	Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLCâ€”Real World Efficacy. Cancers, 2021, 13, 4846.	3.7	19
44	Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Supportive Care in Cancer, 2007, 15, 417-426.	2.2	18
45	Changes in Health-Related Quality of Life During Rehabilitation in Patients With Operable Lung Cancer: A Feasibility Study (PROLUCA). Integrative Cancer Therapies, 2018, 17, 388-400.	2.0	18
46	Treatment of anthracycline extravasation from centrally inserted venous catheters. Oncology Reviews, 2008, 2, 114-116.	1.8	16
47	A Competing Risk Model of First Failure Site after Definitive Chemoradiation Therapy for Locally Advanced Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 559-567.	1.1	16
48	Neuroendocrine neoplasms of the appendix: Characterization of 335 patients referred to the Copenhagen NET Center of Excellence. European Journal of Surgical Oncology, 2021, 47, 1357-1363.	1.0	16
49	A murine experimental anthracycline extravasation model: Pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage. Toxicology, 2010, 269, 67-72.	4.2	15
50	First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: A single institution experience. Acta OncolÃ³gica, 2012, 51, 97-100.	1.8	15
51	Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art. Acta OncolÃ³gica, 2016, 55, 3-14.	1.8	15
52	Reproducibility of MR-Based Attenuation Maps in PET/MRI and the Impact on PET Quantification in Lung Cancer. Journal of Nuclear Medicine, 2018, 59, 999-1004.	5.0	15
53	Management Recommendations for Merkel Cell Carcinomaâ€”A Danish Perspective. Cancers, 2020, 12, 554.	3.7	15
54	(68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 59-72.	1.0	14

#	Article	IF	Citations
55	Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. Diagnostics, 2017, 7, 23.	2.6	13
56	Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Medical Oncology, 2018, 35, 47.	2.5	13
57	Early initiated postoperative rehabilitation enhances quality of life in patients with operable lung cancer: Secondary outcomes from a randomized trial. Lung Cancer, 2020, 146, 285-289.	2.0	13
58	Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patients. Lung Cancer, 2021, 156, 109-116.	2.0	13
59	Prospective Phase II Trial of Prognostication by ⁶⁸Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy. Journal of Nuclear Medicine, 2022, 63, 1371-1377.	5.0	13
60	Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. Current Treatment Options in Oncology, 2022, 23, 806-817.	3.0	13
61	Dexrazoxane for anthracycline extravasation. Expert Review of Anticancer Therapy, 2007, 7, 1081-1088.	2.4	12
62	Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane. Cancer Chemotherapy and Pharmacology, 2012, 69, 573-576.	2.3	12
63	Incidence, Clinical Presentation and Trends in Indication for Diagnostic Work-Up of Small Intestinal and Pancreatic Neuroendocrine Tumors. Diagnostics, 2021, 11, 2030.	2.6	12
64	Brain relapses in chemotherapy-treated small cell lung cancer: a retrospective review of two time-dose regimens of therapeutic brain irradiation. Lung Cancer, 1996, 15, 171-181.	2.0	11
65	Other uses of dexrazoxane: savene, the first proven antidote against anthracycline extravasation injuries. Cardiovascular Toxicology, 2007, 7, 151-153.	2.7	11
66	Early lesion-specific 18F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer. Radiotherapy and Oncology, 2016, 118, 460-464.	0.6	11
67	Improving the prognosis for lung cancer patients. Acta OncolÃ³gica, 2019, 58, 1077-1078.	1.8	11
68	Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients â€“ initial observations. PLoS ONE, 2020, 15, e0231884.	2.5	11
69	PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. PLoS ONE, 2020, 15, e0243900.	2.5	11
70	Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study. Acta OncolÃ³gica, 2022, 61, 409-416.	1.8	11
71	Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancerâ€”a Danish Oncological Lung Cancer Group (DOLG) phase II trial. Lung Cancer, 2008, 60, 252-258.	2.0	10
72	Prognostic Value of 18Fâ€“FDGâ€“PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature. Diagnostics, 2021, 11, 174.	2.6	9

#	Article	IF	Citations
73	PET/CT in therapy evaluation of patients with lung cancer. Expert Review of Anticancer Therapy, 2014, 14, 595-620.	2.4	8
74	¹⁸F-FLT PET/CT Adds Value to ¹⁸F-FDG PET/CT for Diagnosing Relapse After Definitive Radiotherapy in Patients with Lung Cancer: Results of a Prospective Clinical Trial. Journal of Nuclear Medicine, 2021, 62, 628-635.	5.0	8
75	Twenty-five years of chemotherapy in small cell lung cancer sends us back to the laboratory. Cancer Treatment Reviews, 1999, 25, 377-386.	7.7	7
76	Phase II Study of a 3-Day Schedule with Topotecan and Cisplatin in Patients with Previously Untreated Small Cell Lung Cancer and Extensive Disease. Journal of Thoracic Oncology, 2008, 3, 902-906.	1.1	7
77	Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors. Diagnostics, 2020, 10, 881.	2.6	7
78	A short report of 50 patients with gastroenteropancreatic mixed neuroendocrineâ€“non-neuroendocrine neoplasms (MiNEN). Acta OncolÃ³gica, 2021, 60, 808-812.	1.8	7
79	Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. Cancer Chemotherapy and Pharmacology, 2004, 53, 91-93.	2.3	6
80	Increase of Kiâ€67 index and influence on mortality in patients with neuroendocrine neoplasms. Journal of Neuroendocrinology, 2021, 33, e13018.	2.6	6
81	Asbestos-induced lung injury among danish jewelry workers. American Journal of Industrial Medicine, 1994, 26, 755-758.	2.1	5
82	Very Early Response Evaluation by PET/MR in Patients with Lung Cancerâ€”Timing and Feasibility. Diagnostics, 2019, 9, 35.	2.6	5
83	Anthracycline extravasation: a comprehensive review of experimental and clinical treatments. Tumori, 2009, 95, 273-82.	1.1	5
84	Long-term outcomes after video-assisted thoracoscopic surgery in pulmonary large-cell neuroendocrine carcinoma. Surgical Oncology, 2022, 41, 101728.	1.6	5
85	Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases. Case Reports in Medicine, 2015, 2015, 1-4.	0.7	4
86	Primary pulmonary adenocarcinoma in a 16-year-old boy â€“ a five-year follow-up. European Clinical Respiratory Journal, 2016, 3, 32633.	1.5	3
87	Impact of [18F]FDG-PET and [18F]FLT-PET-Parameters in Patients with Suspected Relapse of Irradiated Lung Cancer. Diagnostics, 2021, 11, 279.	2.6	3
88	Initial Experience with 64Cu-DOTATATE Digital PET of Patients with Neuroendocrine Neoplasms: Comparison with Analog PET. Diagnostics, 2021, 11, 350.	2.6	3
89	Metastasizing malignant pleomorphic adenoma in a young man. Apmis, 2007, 115, 866-868.	2.0	2
90	18F-fluorothymidine (FLT)-PET and diffusion-weighted MRI for early response evaluation in patients with small cell lung cancer: a pilot study. European Journal of Hybrid Imaging, 2020, 4, 2.	1.5	2

#	Article	IF	Citations
91	Repeatability of FDG PET/CT metrics assessed in free breathing and deep inspiration breath hold in lung cancer patients. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 127-136.	1.0	2
92	RE: Kesik et al: Melatonin Ameliorates Doxorubicin-induced Skin Necrosis in Rats. Annals of Plastic Surgery, 2010, 65, 511.	0.9	1
93	A Recall Reaction and Call for Action. Onkologie, 2010, 33, 85-86.	0.8	1
94	Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer. Lung Cancer, 2022, 166, 49-57.	2.0	1
95	Activity Dose Reduction in 64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Impact on Image Quality and Lesion Detection Ability. Molecular Imaging and Biology, 2022, 24, 600-611.	2.6	1
96	Pancreatic Islet Cell Tumors. , 2018, , 626-634.		0
97	Title is missing!. , 2020, 15, e0231884.		0
98	Title is missing!. , 2020, 15, e0231884.		0
99	Title is missing!. , 2020, 15, e0231884.		0
100	Title is missing!. , 2020, 15, e0231884.		0